stars 1 stars 2 stars 3

At ViroGates, we believe in staying ahead of illness. We’re proud to have developed and commercialized the suPARnostic® product line that enables the measurement of the biomarker suPAR (soluble urokinase Plasminogen Activator Receptor). suPAR is a powerful indicator of immune activation and inflammation, offering deep insight into a person’s health and disease risk. Our mission is to empower healthcare professionals and individuals with real-time data to detect risks early, make smarter health decisions, and optimize treatments. Designed with long-term healthcare impact in mind, suPARnostic® products are seamlessly integrated by clinicians and laboratory technicians into existing workflows. Fully approved for all major clinical chemistry analyzers, they deliver rapid results in less than 20 minutes.

ViroGates Questions

The ViroGates annual revenue was $1 million in 2026.

Jakob Knudsen is the CEO of ViroGates.

8 people are employed at ViroGates.

The NAICS codes for ViroGates are [325413, 325, 32541, 3254, 32].

The SIC codes for ViroGates are [283, 28].

Top ViroGates Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users